| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Beng-Choon Ho, Amy B Barry, Julie A Koeppel, John Macleod, Andy Boyd, Anthony David, Daniel S O'Lear. Recreational Marijuana Use, Adolescent Cognitive Development, and Schizophrenia Susceptibility. Biological psychiatry global open science. vol 3. issue 2. 2023-05-01. PMID:37124347. |
we investigated how low marijuana (mj) use levels, the typical use pattern in most adolescent users, affect cognitive maturation and schizophrenia risk. |
2023-05-01 |
2023-08-14 |
Not clear |
| Shinnyi Chou, Kenneth N Fish, David A Lewis, Robert A Swee. Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study. bioRxiv : the preprint server for biology. 2023-04-24. PMID:37090672. |
individuals with schizophrenia are at elevated genetic risks for comorbid cannabis use, and often experience exacerbations of cognitive and psychotic symptoms when exposed to cannabis. |
2023-04-24 |
2023-08-14 |
human |
| Peter Allebeck, Tove Gunnarsson, Andreas Lundin, Sofia Löfving, Henrik Dal, Stanley Zammi. Does a history of cannabis use influence onset and course of schizophrenia? Acta psychiatrica Scandinavica. 2023-04-24. PMID:37094811. |
does a history of cannabis use influence onset and course of schizophrenia? |
2023-04-24 |
2023-08-14 |
Not clear |
| Peter Allebeck, Tove Gunnarsson, Andreas Lundin, Sofia Löfving, Henrik Dal, Stanley Zammi. Does a history of cannabis use influence onset and course of schizophrenia? Acta psychiatrica Scandinavica. 2023-04-24. PMID:37094811. |
while evidence strongly supports a causal effect of cannabis on psychosis, it is less clear whether the symptom pattern, clinical course, and outcomes differ in cases of schizophrenia with and without a background of cannabis use. |
2023-04-24 |
2023-08-14 |
Not clear |
| Noah Lorincz-Comi, Yihe Yang, Gen Li, Xiaofeng Zh. MRBEE: A novel bias-corrected multivariable Mendelian Randomization method. bioRxiv : the preprint server for biology. 2023-04-17. PMID:37066391. |
in two independent real data analyses, we discovered that the causal effect of bmi on coronary artery disease risk is entirely mediated by blood pressure, and that existing mr methods may underestimate the causal effect of cannabis use disorder on schizophrenia risk compared to mrbee. |
2023-04-17 |
2023-08-14 |
human |
| Linda Levi, Mor Bar-Haim, Inge Winter-van Rossum, Michael Davidson, Stefan Leucht, Wolfgang W Fleischhacker, Jinyoung Park, John M Davis, Renè S Kahn, Mark Weise. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophrenia bulletin. 2023-03-31. PMID:36999551. |
cannabis use and symptomatic relapse in first episode schizophrenia: trigger or consequence? |
2023-03-31 |
2023-08-14 |
Not clear |
| Zahra Mojtahedi, Ying Guo, Pearl Kim, Parsa Khawari, Hailey Ephrem, Jay J She. Mental Health Conditions- and Substance Use-Associated Emergency Department Visits during the COVID-19 Pandemic in Nevada, USA. International journal of environmental research and public health. vol 20. issue 5. 2023-03-11. PMID:36901398. |
objectives-this study examined the changes in ed visits associated with more common and serious mental health conditions (suicidal ideation, suicide attempts, and schizophrenia) and more commonly used substances (opioids, cannabis, alcohol, and cigarettes) in nevada during the covid-19 pandemic in 2020 and 2021 compared with the pre-pandemic period. |
2023-03-11 |
2023-08-14 |
Not clear |
| Zac J S Yeap, Justine Marsault, Tony P George, Romina Mizrahi, Rachel A Rabi. Does tobacco dependence worsen cannabis withdrawal in people with and without schizophrenia-spectrum disorders? The American journal on addictions. 2023-02-23. PMID:36815595. |
rates of cannabis use disorder (cud) are higher in people with schizophrenia than in the general population. |
2023-02-23 |
2023-08-14 |
Not clear |
| Xiaofeng Zhu, Noah Lorincz-Comi, Yihe Yang, Gen L. MRBEE: A novel bias-corrected multivariable Mendelian Randomization method. Research square. 2023-02-13. PMID:36778480. |
in two independent real data analyses, we observed that the causal effect of bmi on coronary artery disease risk is completely mediated by blood pressure, and that existing mr methods drastically underestimate the causal effect of cannabis use disorder on schizophrenia risk compared to mrbee. |
2023-02-13 |
2023-08-14 |
human |
| Thomas Schnell, Christina-Marie Grömm, Nils Klöckne. Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use. Scientific reports. vol 13. issue 1. 2023-01-13. PMID:36639397. |
but although prevalence of consumption as well as potency of cannabis increased, the incidence of schizophrenia remained stable. |
2023-01-13 |
2023-08-14 |
Not clear |
| Emma C Johnson, Sarah M C Colbert, Paul W Jeffries, Rebecca Tillman, Tim B Bigdeli, Nicole R Karcher, Grace Chan, Samuel Kuperman, Jacquelyn L Meyers, John I Nurnberger, Martin H Plawecki, Louisa Degenhardt, Nicholas G Martin, Chella Kamarajan, Marc A Schuckit, Robin M Murray, Danielle M Dick, Howard J Edenberg, Deepak Cyril D'Souza, Marta Di Forti, Bernice Porjesz, Elliot C Nelson, Arpana Agrawa. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. Schizophrenia bulletin. 2022-12-22. PMID:36545904. |
risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (ples). |
2022-12-22 |
2023-08-14 |
Not clear |
| Abdul Qayyum Khan, Lukas Thielen, Gwenaëlle Le Pen, Marie-Odile Krebs, Oussama Kebir, Adrian Groh, Maximilian Deest, Stefan Bleich, Helge Frieling, Kirsten Jah. Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence. Schizophrenia (Heidelberg, Germany). vol 8. issue 1. 2022-12-08. PMID:36481661. |
many risk factors, including childhood trauma, viral infections, migration, and the use of cannabis, are associated with schizophrenia. |
2022-12-08 |
2023-08-14 |
rat |
| Shariful A Syed, Ashley M Schnakenberg Martin, Jose A Cortes-Briones, Patrick D Skosni. The Relationship Between Cannabinoids and Neural Oscillations: How Cannabis Disrupts Sensation, Perception, and Cognition. Clinical EEG and neuroscience. 2022-11-25. PMID:36426543. |
finally, we highlight important clinical implications of such oscillatory disruptions, such as the potential relationship between cannabis use, altered neural synchrony, and disruptions in sensation, perception, and cognition, which are perturbed in disorders such as schizophrenia. |
2022-11-25 |
2023-08-14 |
Not clear |
| Gabriela Visini, Samara Brown, Katrina Weston-Green, Cynthia Shannon Weickert, Rose Chesworth, Tim Kar. The effects of preventative cannabidiol in a male Frontiers in cellular neuroscience. vol 16. 2022-11-21. PMID:36406747. |
the effects of preventative cannabidiol in a male cannabidiol (cbd) is a non-intoxicating cannabinoid with antipsychotic-like properties, however it's potential to prevent schizophrenia development has not been thoroughly investigated. |
2022-11-21 |
2023-08-14 |
Not clear |
| Liu Liu, Jianxing Liu, Ming Zhao, Meiming Cai, Fanzhang Lei, Xiaofeng Zeng, Bofeng Zh. A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021. Frontiers in pharmacology. vol 13. 2022-11-21. PMID:36408229. |
great importance has been attached to the pharmacology or pharmacy values of cannabidiol, especially in the treatment of neuropsychiatric disorders, such as epilepsy, anxiety, and schizophrenia. |
2022-11-21 |
2023-08-14 |
Not clear |
| Ophélie Rault, Bruno Romeo, Florence Butlen-Ducuing, Eirini Rari, Amine Benyamina, Catherine Martell. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. Journal of psychiatric research. vol 156. 2022-11-21. PMID:36410310. |
impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: a systematic review and meta-analysis. |
2022-11-21 |
2023-08-14 |
Not clear |
| Ophélie Rault, Bruno Romeo, Florence Butlen-Ducuing, Eirini Rari, Amine Benyamina, Catherine Martell. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. Journal of psychiatric research. vol 156. 2022-11-21. PMID:36410310. |
compared with the general population, there are more cannabis users among patients suffering from schizophrenia and this consumption seems to impact the course and the treatment of their pathology. |
2022-11-21 |
2023-08-14 |
Not clear |
| Ophélie Rault, Bruno Romeo, Florence Butlen-Ducuing, Eirini Rari, Amine Benyamina, Catherine Martell. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. Journal of psychiatric research. vol 156. 2022-11-21. PMID:36410310. |
the aim of this meta-analysis and systematic review was to assess the impact of cannabis use on the efficacy of treatments, more particularly regarding the antipsychotic dosage, symptoms evolution, therapeutic resistance and the risk of relapse in patients with schizophrenia taking medication. |
2022-11-21 |
2023-08-14 |
Not clear |
| Ophélie Rault, Bruno Romeo, Florence Butlen-Ducuing, Eirini Rari, Amine Benyamina, Catherine Martell. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. Journal of psychiatric research. vol 156. 2022-11-21. PMID:36410310. |
this meta-analysis provides evidence that previous cannabis use, or occasional use, in patients with schizophrenia taking medication does not impact antipsychotic efficacy as described by antipsychotic dosage or panss score. |
2022-11-21 |
2023-08-14 |
Not clear |
| Karin J H Verweij, Jacqueline M Vink, Abdel Abdellaoui, Nathan A Gillespie, Eske M Derks, Jorien L Treu. The genetic aetiology of cannabis use: from twin models to genome-wide association studies and beyond. Translational psychiatry. vol 12. issue 1. 2022-11-21. PMID:36411281. |
studies that applied multivariate methods (twin models, genetic correlation analysis, polygenic score analysis, genomic structural equation modelling, mendelian randomisation) indicate that there is considerable genetic overlap between cannabis use and other traits (especially other substances and externalising disorders) and some evidence for causal relationships (most convincingly for schizophrenia). |
2022-11-21 |
2023-08-14 |
Not clear |